Logo Image
News
OncClubAll Oncology NewsClinical Trials in Focus
Watch
Expert ConversationsShows & PodcastsNews & Analysis
Conferences
Conference CoverageConference Listing
Events
Giants of Cancer CareCME/CEScientific InterchangesState of the Science SummitNational Fellows ForumWebinars
More
Partners
Publications
All PublicationsSupplements
Resources
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker Consortium

Subscribe

  • News
  • Watch
  • Conferences
  • Events
  • Partners
  • Publications
  • Resources
  • Biomarker Consortium
  • Subscribe
  • AI for Oncology
  • Biosimilars
  • Brain Cancer
  • Breast Cancer
    • HER2+ Breast Cancer
  • CAR T-Cell Therapy
  • Disparities in Cancer Care
  • Gastrointestinal Cancer
    • Pancreatic Cancer
    • Hepatocellular Carcinoma
    • Gastric Cancer
    • Colorectal Cancer
  • Genitourinary Cancers
    • Urothelial Cancer
    • Prostate Cancer
  • Global Oncology
  • Graft-vs-Host Disease
  • Gynecologic Oncology
    • Ovarian Cancer
  • Head & Neck Cancers
  • Hematologic Oncology
    • Chronic Lymphocytic Leukemia
    • Non-Hodgkin Lymphoma
    • Mantle Cell Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Neoplasms
  • Immuno-Oncology
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Oncology Business Management
  • Pediatric Oncology
  • Precision Medicine in Oncology®
  • Sarcomas
  • Supportive Care
Spotlight -
The OncLive Insider app is live!|
CME Opportunities
Advertisement

Jason Jincong Freeman, PhD

Advertisement

Articles by Jason Jincong Freeman, PhD

Jason Jincong Freeman, PhD

Freeman on Mortality Differences Across Racial Groups in Male Patients With Breast Cancer

ByJason Jincong Freeman, PhD
December 6th 2023

Jason Jincong Freeman, discusses mortality differences across various racial groups in male patients with stage I, II, or III breast cancer.

Advertisement

Latest Updated Articles



    Advertisement
    Advertisement

    Trending on OncLive

    1

    FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer

    2

    Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC

    3

    Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC

    4

    Etentamig Meets PFS, ORR Primary End Points in Triple-Class Exposed R/R Myeloma

    5

    A New Player in the Adjuvant Setting? GLP-1 Agonists and the Fight Against Breast Cancer Metastasis

    • Advertise
    • About OncLive
    • Editorial Board
    • MJH Life Sciences brands
    • Contact Us
    • Privacy
    • Terms & Conditions
    • Do Not Sell My Information
    Contact Info

    259 Prospect Plains Rd, Bldg H
    Cranbury, NJ 08512

    Brand Logo
    Download on Apple
    Download on Google Play

    © 2026 MJH Life Sciences®

    All rights reserved.

    Home
    About Us
    News
    Contact Us